Pfizer (PFE): CEO received 22 units
Albert Bourla, CEO at Pfizer, reported a grant / award of 22 units.
- 22
- Derivative units · @ $26.79
- Traded
- Aug 14, 2026
- Filed
- Aug 17, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Nov 26, 2024CongressDisclosed sale of PFE — reported range $1,001 - $15,000
- Mar 10, 2025CongressDisclosed sale of PFE — reported range $15,001 - $50,000
- Mar 24, 2026CongressDisclosed sale of PFE — reported range $50,001 - $100,000
- Jun 8, 2026CongressDisclosed sale of PFE — reported range $15,001 - $50,000
- Jun 18, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 16, 2026, Dave Denton notified Pfizer Inc. (the “Company”) that he will step down from his current position as Chief Financial Officer effective August 15, 2026 for a professional opportunity outside of the pharmaceutical industry in consumer goods, and that his departure is not related to the Company’s financial or operating results or to any disagreements with the Company regarding the Company’s financial,…”
- Jun 24, 2026FDAFDA drug approval: Ibrance
- Jun 24, 2026FDAFDA drug approval: Ibrance
- Jul 6, 2026Government · Federal Register noticeEndo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Jul 15, 2026Federal contract · $5K obligatedDepartment of Defense awarded Pfizer: $4.9K obligated to date
- Jul 20, 2026Government · Federal Register noticeForeign-Trade Zone (FTZ) 43, Notification of Proposed Production Activity; Pfizer Inc.; (Pharmaceutical Products); Kalamazoo and Portage, Michigan
- Jul 30, 2026Federal contract · $4K obligatedDepartment of Defense awarded Pfizer: $3.9K obligated to date
- Aug 4, 2026Company filing · Form 8-K · ResultsReported its results
- Aug 5, 2026Insider · 3 peopleInsiders: 2 purchases (~$2.0M), 1 sale (~$83K)
- Aug 12, 2026Insider · Their first buy on recordCEO purchased ~$1M of PFE shares in the open market
What came next
- Aug 21, 2026Government · Federal Register noticeAdvisory Committee; Oncologic Drugs Advisory Committee; Renewal
- Sep 4, 2026FDARecall: Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA, Vial NDC…
- Sep 25, 2026Government · Federal Register noticeJeffrey Thies: Final Debarment Order
- Sep 29, 2026FDARecall: Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC…
- Sep 29, 2026FDARecall: Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 1000-count bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC…
- Oct 7, 2026FDAFDA drug approval: Tukysa
- Oct 26, 2026FDAFDA drug approval: Talzenna
- Oct 26, 2026FDAFDA drug approval: Talzenna
- Oct 30, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 3, 2026, Pfizer Inc. (the “Company”) announced that the Board of Directors of the Company unanimously elected Cecile Guegan to serve as Chief Financial Officer, Executive Vice President of the Company, effective November 1, 2026 (the “Effective Date”).”
- Nov 3, 2026Company filing · Form 8-K · ResultsReported its results
- Nov 13, 2026Government · Federal Register noticeDetermination That DIBENZYLINE (Phenoxybenzamine Hydrochloride) Oral Capsule, 10 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Pfizer
For Pfizer, OQRO holds 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PFE page.
Other recent filings by Albert Bourla, Chairman & CEO
The full history of Albert Bourla, Chairman & CEO is on the profile page.
How this filing works
Explore the data
Common questions
Which Pfizer (PFE) insider traded, and how much?
Albert Bourla, CEO at Pfizer, reported a grant / award of 22 units. At $26.79.
When did it happen, and when was it made public?
Traded: Aug 14, 2026. Filed: Aug 17, 2026. That is 3 days between the two dates.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Pfizer recently?
For Pfizer, OQRO holds 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days. They are listed on the PFE page.
Does this mean PFE stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Pfizer
- SEC Form 13F-HRNov 16, 2026
- USAspending.gov award recordNov 12, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
Everything OQRO holds on this company is on its PFE page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
